These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33988379)

  • 1. Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.
    Kress BJ; Kim DH; Mayo JR; Farris JT; Heck B; Sarver JG; Andy D; Trendel JA; Heck BE; Erhardt PW
    J Med Chem; 2021 May; 64(10):6996-7032. PubMed ID: 33988379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor delta agonist attenuates nicotine suppression effect on human mesenchymal stem cell-derived osteogenesis and involves increased expression of heme oxygenase-1.
    Kim DH; Liu J; Bhat S; Benedict G; Lecka-Czernik B; Peterson SJ; Ebraheim NA; Heck BE
    J Bone Miner Metab; 2013 Jan; 31(1):44-52. PubMed ID: 22945906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
    Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
    Epple R; Cow C; Xie Y; Azimioara M; Russo R; Wang X; Wityak J; Karanewsky DS; Tuntland T; Nguyêñ-Trân VT; Cuc Ngo C; Huang D; Saez E; Spalding T; Gerken A; Iskandar M; Seidel HM; Tian SS
    J Med Chem; 2010 Jan; 53(1):77-105. PubMed ID: 19928766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold.
    Teske KA; Rai G; Nandhikonda P; Sidhu PS; Feleke B; Simeonov A; Yasgar A; Jadhav A; Maloney DJ; Arnold LA
    ACS Comb Sci; 2017 Oct; 19(10):646-656. PubMed ID: 28825467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Design and synthesis of peroxisome proliferator-activated receptor (PPAR) delta agonists and its implication to the driving force to elicit PPAR delta selectivity].
    Kasuga J; Oyama T; Nakagome I; Aoyama A; Sako K; Makishima M; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
    Yakugaku Zasshi; 2009 Jun; 129(6):709-18. PubMed ID: 19483413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor delta regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury.
    Yin KJ; Deng Z; Hamblin M; Xiang Y; Huang H; Zhang J; Jiang X; Wang Y; Chen YE
    J Neurosci; 2010 May; 30(18):6398-408. PubMed ID: 20445066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of oligodendrocyte progenitor cell maturation by PPARδ: effects on bone morphogenetic proteins.
    Vittoria Simonini M; Polak PE; Boullerne AI; Peters JM; Richardson JC; Feinstein DL
    ASN Neuro; 2010 Jan; 2(1):e00025. PubMed ID: 20001953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.
    Kasuga J; Nakagome I; Aoyama A; Sako K; Ishizawa M; Ogura M; Makishima M; Hirono S; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2007 Aug; 15(15):5177-90. PubMed ID: 17532641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of a partial PPARdelta agonist.
    Pettersson I; Ebdrup S; Havranek M; Pihera P; Korínek M; Mogensen JP; Jeppesen CB; Johansson E; Sauerberg P
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4625-9. PubMed ID: 17560785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARδ agonist GW0742 ameliorates Aβ1-42-induced hippocampal neurotoxicity in mice.
    An YQ; Zhang CT; Du Y; Zhang M; Tang SS; Hu M; Long Y; Sun HB; Hong H
    Metab Brain Dis; 2016 Jun; 31(3):663-71. PubMed ID: 26864581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.
    Iwashita A; Muramatsu Y; Yamazaki T; Muramoto M; Kita Y; Yamazaki S; Mihara K; Moriguchi A; Matsuoka N
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1087-96. PubMed ID: 17167170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of an orally available "Y"-shaped biaryl peroxisome proliferator-activated receptor δ agonist.
    Kim DS; Lee J; Londhe AM; Kadayat TM; Joo J; Hwang H; Kim KH; Pae AN; Chin J; Cho SJ; Kang H
    Bioorg Med Chem; 2018 Aug; 26(15):4382-4389. PubMed ID: 30054191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of PPARδ agonists GW1516 and GW0742 and their metabolites in human urine.
    Sobolevsky T; Dikunets M; Sukhanova I; Virus E; Rodchenkov G
    Drug Test Anal; 2012 Oct; 4(10):754-60. PubMed ID: 22977012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis.
    Polak PE; Kalinin S; Dello Russo C; Gavrilyuk V; Sharp A; Peters JM; Richardson J; Willson TM; Weinberg G; Feinstein DL
    J Neuroimmunol; 2005 Nov; 168(1-2):65-75. PubMed ID: 16098614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.
    Sznaidman ML; Haffner CD; Maloney PR; Fivush A; Chao E; Goreham D; Sierra ML; LeGrumelec C; Xu HE; Montana VG; Lambert MH; Willson TM; Oliver WR; Sternbach DD
    Bioorg Med Chem Lett; 2003 May; 13(9):1517-21. PubMed ID: 12699745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice.
    Matsushita Y; Ogawa D; Wada J; Yamamoto N; Shikata K; Sato C; Tachibana H; Toyota N; Makino H
    Diabetes; 2011 Mar; 60(3):960-8. PubMed ID: 21270242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PPARδ agonist GW0742 restores neuroimmune function by regulating Tim-3 and Th17/Treg-related signaling in the BTBR autistic mouse model.
    Ahmad SF; Nadeem A; Ansari MA; Bakheet SA; Alshammari MA; Attia SM
    Neurochem Int; 2018 Nov; 120():251-261. PubMed ID: 30227151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.
    Li Z; Chen Y; Zhou Z; Deng L; Xu Y; Hu L; Liu B; Zhang L
    Eur J Med Chem; 2019 Feb; 164():352-365. PubMed ID: 30605833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.